(Renal Cell Carcinoma) Is Keytruda Plus Inlyta Effective? KEYNOTE-426 5-Year Follow-Up Results
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
- July 5, 2023
- 1 min read
At ASCO 2023, held in Chicago from June 2–6, 2023, Brian I. Rini and colleagues from Vanderbilt-Ingram Cancer Center presented 5-year follow-up results from the KEYNOTE-426 Phase 3 clinical trial evaluating the efficacy and safety of pembrolizumab (Keytruda) plus axitinib (Inlyta) in treatment-naive renal cell carcinoma patients.
Trial Design:
The KEYNOTE-426 Phase 3 trial randomized treatment-naive renal cell carcinoma patients (N=861) 1:1 to:
- Pembrolizumab 200 mg + axitinib 5 mg twice daily (3-week cycle, N=432)
- Sunitinib (Sutent) 50 mg once daily
Primary endpoints were PFS and OS.
Results at median follow-up of 67.2 months:
| Endpoint | Keytruda + Inlyta | Sutent |
|---|---|---|
| 5-year OS rate | 41.9% | 37.1% |
| 5-year PFS rate | 18.3% | 7.3% |
| Median duration of response | 23.6 months | 15.3 months |
Safety:
Treatment discontinuation rate: Keytruda + Inlyta 62.2% (237/381 patients) vs. Sutent 73.9% (300/406 patients). No new safety signals were identified.
Conclusion: Based on the KEYNOTE-426 5-year follow-up analysis, Brian I. Rini and colleagues concluded that Keytruda plus Inlyta demonstrated improved 5-year OS and PFS compared to Sutent monotherapy in treatment-naive renal cell carcinoma patients, supporting its continued use as a standard of care.
Source: https://meetings.asco.org/abstracts-presentations/219855
Renal Cell Carcinoma | Immunotherapy | Keytruda | Inlyta | KEYNOTE-426
-
Clinical Trial Medications
-
Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4